



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/725,965
				Filing Date	December 2, 2003
				First Named Inventor	Erik Buntinx
				Art Unit	1617
				Examiner Name	Umamaheswari Ramachandran
Sheet	2	of	2	Attorney Docket Number	29248/18

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/U.R./	3	MÜLLER T, entitled "Drug treatment of non-motor symptoms in Parkinson's disease," Expert Opinion on Pharmacotherapy, 2002, Vol. 3, No. 4, pp. 381-388.	
	4	PERMAX prescription information, Eli Lilly Company, ( <a href="http://www.fda.gov/medwatch/safety/2003/permax_PI.pdf">http://www.fda.gov/medwatch/safety/2003/permax_PI.pdf</a> ), revised October 2, 2003, pp. 1-2.	
	5	USPTO Office Action dated 05/03/2007 in connection with related Application Serial No. 10/803,793 filed 03/18/2004, Examiner Carlic K. Huynh, Art Unit 1617.	
	6	USPTO Office Action dated 0810/2007 in connection with related Application Serial No. 10/984,683 filed 11/09/2004, Examiner Carlic K. Huynh, Art Unit 1617.	
	7	USPTO Office Action dated 10/02/2007 in connection with related Application Serial No. 10/752,423 filed 01/06/2004, Examiner Umamaheswari Ramachandran, Art Unit 1617.	
↓	8	USPTO Office Action dated 10/19/2007 in connection with related Application Serial No. 10/803,793 filed 03/18/2004, Examiner Carlic K. Huynh, Art Unit 1617.	

Examiner Signature	/Umamaheswari Ramachandran/	Date Considered	01/15/2008
--------------------	-----------------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08A (04-07)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>			<b>Complete if Known</b>		
			Application Number	10/725,965	
			Filing Date	December 2, 2003	
			First Named Inventor	Erik Buntinx	
			Art Unit	1617	
			Examiner Name	Umamaheswari Ramachandran	
Sheet	2	of	2	Attorney Docket Number	29248/18

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/U.R./	4	HUBBLE J P et al., entitled "Pre-clinical studies of pramipexole: clinical relevance," European Journal of Neurology Supplement, 2000, Vol. 7 (Suppl. 1), pp. 15-20.	
/U.R./	5	SILVER D E et al., entitled "Initiating therapy for Parkinson's disease," Neurology, 1998, Vol. 50 (Suppl. 6), pp. S18-S22.	

Examiner Signature	/Umamaheswari Ramachandran/	Date Considered	01/15/2008
--------------------	-----------------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/725,965
		Filing Date	December 2, 2003
		First Named Inventor	Erik Buntinx
		Art Unit	1617
		Examiner Name	Umamaheswari Ramachandran
Sheet	1	of	1
		Attorney Docket Number	29248/18

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/U.R./	12	www.biam2.org/www/Sub2783.html, entitled "Pipamperone Dichlorhydrate," November 12, 2000, 1-4.	
	13	www.adiph.org/pic/pedia-neuroleptiques.pdf, entitled "Medicaments Psychotropes: Posologies Chez L'Enfant et L'Adolescent," August 2001, 1-3.	
	14	HEISER P et al., entitled "The selective serotonin reuptake inhibitors and the newer antidepressants in child and adolescent psychiatry," Zeitschrift fur Kinder - und Jugendpsychiatrie und Psychotherapie Switzerland 30: 2002, 173-183.	
	15	CARRIER PR et al., "Synthesis of a Potent Wide-Spectrum Serotonin-, Norepinephrine-, Dopamine- reuptake inhibitor (SNDRI) and a species-selective dopamine reuptake inhibitor based on the gamma-amino alcohol functional group, Bioorgan. Medicin. Chem. Let. 8, 1998, 487-492.	
	16	FITZGERALD K D et al., entitled "Risperidone Augmentation of Serotonin Reuptake Inhibitor Treatment of Pediatric Obsessive Compulsive Disorder," Journal of Child and Adolescent Psychopharmacology, Vol. 9, No. 2, 1999, 115-123.	
	17	MCDUGLE C J et al., entitled "A Double-blind, Placebo-Controlled Study of Risperidone Addition in Serotonin Reuptake Inhibitor-Refractory Obsessive-compulsive Disorder," Arch Gen Psychiatry, Vol. 57, August 2000, 794-801.	
	18	MAINA G et al., entitled "Antipsychotic augmentation for treatment resistant obsessive-compulsive disorder: what if antipsychotic is discontinued," Int. Clin. Psychopharm, 18, 2003, 23-28.	
	19	HIROSE S et al., entitled "An Open Pilot Study Combining Risperidone and a Selective Serotonin Reuptake Inhibitor as Initial Antidepressant Therapy," J. Clin. Psych. 63, 2002, 733-736.	
↓	20	Truffinet P et al., Placebo-controlled study of the D4/5-HT2A antagonist fananserin in the treatment of schizophrenia. Am J. Psychiatry 156: 419-425, 1999.	

Examiner Signature	/Umamaheswari Ramachandran/	Date Considered	01/15/2008
--------------------	-----------------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	10/725,965
		Filing Date	December 2, 2003
		First Named Inventor	Erik Buntinx
		Art Unit	1617
		Examiner Name	Umamaheswari Ramachandran
Sheet <u>1</u> of <u>1</u>	Attorney Docket Number	29248/18	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/U.R./	12	www.biam2.org/www/Sub2783.html, entitled "Pipamperone Dichlorhydrate," November 12, 2000, 1-4.	
	13	www.adiph.org/pic/pedia-neuroleptiques.pdf, entitled "Medicaments Psychotropes: Posologies Chez L'Enfant et L'Adolescent," August 2001, 1-3.	
	14	HEISER P et al., entitled "The selective serotonin reuptake inhibitors and the newer antidepressants in child and adolescent psychiatry," Zeitschrift fur Kinder - und Jugendpsychiatrie und Psychotherapie Switzerland 30: 2002, 173-183.	
	15	CARLIER PR et al., "Synthesis of a Potent Wide-Spectrum Serotonin-, Norepinephrine-, Dopamine- reuptake inhibitor (SNDRI) and a species-selective dopamine reuptake inhibitor based on the gamma-amino alcohol functional group, Bioorgan. Medicin. Chem. Let. 8, 1998, 487-492.	
	16	FITZGERALD K D et al., entitled "Risperidone Augmentation of Serotonin Reuptake Inhibitor Treatment of Pediatric Obsessive Compulsive Disorder," Journal of Child and Adolescent Psychopharmacology, Vol. 9, No. 2, 1999, 115-123.	
	17	MCDUGLE C J et al., entitled "A Double-blind, Placebo-Controlled Study of Risperidone Addition in Serotonin Reuptake Inhibitor-Refractory Obsessive-compulsive Disorder," Arch Gen Psychiatry, Vol. 57, August 2000, 794-801.	
	18	MAINA G et al., entitled "Antipsychotic augmentation for treatment resistant obsessive-compulsive disorder: what if antipsychotic is discontinued," Int. Clin. Psychopharm, 18, 2003, 23-28.	
	19	HIROSE S et al., entitled "An Open Pilot Study Combining Risperidone and a Selective Serotonin Reuptake Inhibitor as Initial Antidepressant Therapy," J. Clin. Psych. 63, 2002, 733-736.	
✓	20	Truffinet P et al., Placebo-controlled study of the D4/5-HT2A antagonist fananserin in the treatment of schizophrenia. Am J. Psychiatry 156: 419-425, 1999.	

Examiner Signature	/Umamaheswari Ramachandran/	Date Considered	01/15/2008
--------------------	-----------------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(Use as many sheets as necessary)*

Sheet	2	of	6
-------	---	----	---

**Complete if Known**

Application Number	10/725,965
Filing Date	December 2, 2003
First Named Inventor	Erik Buntinx
Art Unit	1617
Examiner Name	Jennifer M. Kim
Attorney Docket Number	29248/18

## U. S. PATENT DOCUMENTS

[illegible]

**FOREIGN PATENT DOCUMENTS**

[illegible]

**Examiner  
Signature**

/Umamaheswari Ramachandran/

Date	
Considered	

01/15/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number 10/725,965

Filing Date December 2, 2003

First Named Inventor Erik Buntinx

Art Unit 1617

Examiner Name Jennifer M. Kim

Attorney Docket Number 29248/18

Sheet 3 of 6

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/U.R./	10	SCHINDLER T et al., entitled "Palliative medical management in anxiety and depression," Zeitschrift Fur Allgemeinmedizin, Vol. 74, No. 21, November 5, 1998, pp. 973-978.	
	11	VOLMAT R et al., entitled "The treatment of depressions by Cledial. Evolution and clinical state and handwriting," Psychologie Medicale, Vol. 18, No. 10, 1986, pp. 1615-1622.	
	12	FOUKS et al., entitled "Treatment of character disorders with a new butyrophenone: R. 3345 or pipamperone," Annales Medico-Psychologiques, Vol. 124, No. 5, 1966, pp. 677-681.	
	13	SQUELART P et al., entitled "Pipamperone (Dipiperon), a useful sedative neuroleptic drug in troublesome chronic psychotic patients," Acta Psychiatrica Belgica, Vol. 77, No. 2, March 1977, pp. 284-293.	
	14	KOCH H J et al., entitled "Successful therapy of tardive dyskinesia in a 71-year-old woman with a combination of tetrabenazine, olanzapinr and tiapride," International Journal of Clinical Practice, Vol. 57, No. 2, March 2003, pp. 147-149.	
	15	DIEBOLD K et al., entitled "Are psychoactive-drug-induced changes in plasma lipid and lipoprotein levels of significance for clinical remission in psychiatric disorders?" Pharmacopsychiatry, 1998, 31/2, pp. 60-67.	
	16	GROZINGER M et al., entitled "Melperone is an inhibitor of the CYP2D6 catalyzed O-demethylation of venlafaxine," Pharmacopsychiatry, Vol. 36, No. 1, January 3003, pp. 3-6.	
	17	PERUGI G et al., entitled "Effectiveness of Adjunctive Gabapentin in Resistant Bipolar Disorder: Is it due to anxious-alcohol abuse comorbidity?" Journal of clinical Psychopharmacology, Vol. 22, No. 6, 2002, pp. 584-591.	
	18	WIELING W et al., entitled "Initial orthostatic hypotension as a cause of recurrent syncope: A case report," Clinical Autonomic Research, Vol. 11, No. 4, 2001, pp. 269-270.	
↓	19	DATABASE PHARMAPROJECTS 'ONLINE! PJB Publications Ltd., December 1999. Caesar accession no. 1498	

Examiner Signature	/Umamaheswari Ramachandran/	Date Considered	01/15/2008
--------------------	-----------------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/725,965		
		Filing Date	December 2, 2003		
		First Named Inventor	Erik Buntinx		
		Art Unit	1617		
		Examiner Name	Jennifer M. Kim		
Sheet	4	of	6	Attorney Docket Number	29248/18

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/U.R./	20	ADLER L et al., entitled "Praxis Der Stationaeren Akutbehandlung Von Manien Retrospektive Vergleichsuntersuchung An Je 100 Patienten Zweier Psychiatrischer Sentren Practice of In-Patient Acute Treatment of Manias," Fortschritte Der Neurologie Psychiatrie, Stuttgart, Vol. 62, No. 12, 1994, pp. 479-488.	
	21	ANSOMS C et al., entitled "Sleep disorders in patients with severe mental depression: double-blind placebo-controlled evaluation of the value of pipamerone (Dipiperon)," Acta Psychiatrica Scandinavica, Vol. 55, No. 2, February 1977, pp. 116-122.	
	22	LEYSEN J E et al., entitled "Receptor interactions of new antipsychotics: Relation to Pharmacodynamic and Clinical Effects," International Journal of Psychiatry in Clinical Practice, Vol. 2, No. 1, 1998, pp. S03-S17.	
	23	VANHOENACKER P et al., entitled "Efficient Expression of the Human Dopamine D4.2 Receptor: Positive Influence of Pipamperone on Expression Levels," Abstracts of the Society for Neuroscience, Vol. 26, No. 1/2, 2000.	
	24	SCHOTTE A et al., entitled "Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding," Psychopharmacology, Vol. 124, No. 1-2, 1996, pp. 57-73.	
	25	WOGGON B, entitled "Pharmakologische depressionbehandlung pharmacological treatment of depression," Therapeutische Umschau, Vol. 57, No. 2, 2000, pp. 81-89.	
	26	VAN DE VIJVER DAMC et al., entitled "Antipsychotics and Parkinson's disease: Association with disease and drug choice during the first 5 years of antiparkinsonian durg treatment," Eur J Clin Pharmacology, Vol 58, 2002, pp. 157-161.	
↓			
	27	JOVIC NI et al., entitled "Phenomenology and treatment of delirium in Alzheimer's disease!" Revue Medicale De La Suisse Romande, Vol. 117, No. 9, September 1997, pp. 655-658.	

Examiner Signature	/Umamaheswari Ramachandran/	Date Considered	01/15/2008
--------------------	-----------------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/725,965		
		Filing Date	December 2, 2003		
		First Named Inventor	Erik Buntinx		
		Art Unit	1617		
		Examiner Name	Jennifer M. Kim		
Sheet	5	of	6	Attorney Docket Number	29248/18

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/U.R./	28	ENGELBORGH S et al., entitled "Amino acids and biogenic amines in cerebrospinal fluid of patients with Parkinson's disease," Neurochemical Research, Vol. 28, No. 8, August 2003, pp. 1145-1150.	
	29	NEWMAN-TANCREDIT A et al., [35S]-guanosine-5'-0-(3-thio) triphosphate binding as a measure of efficacy at human recombinant dopamine D-4.4 receptors: Actions of antiparkinsonian and antipsychotic agents. Journal of Pharmacology and Experimental Therapeutics, Vol. 282, No. 1, 1997 pp. 181-191.	
	30	TARAZI F I et al., entitled "Role of dopamine D4 receptors in neuropsychiatric disorders," Journal of Neurochemistry, Vol. 81, No. Supplement 1, June 2002, p. 33. Abstract	
	31	TARAZI F I et al., entitled "Dopamine D4 Receptors: Significance for Molecular Psychiatry at the Millennium," Molecular Psychiatry, Vol. 4, No. 6, November 1999, pp. 529-538.	
	32	LEOPOLD N A, entitled "Risperidone treatment of drug-related psychosis in patients with parkinsonism," Movement Disorders. Vol. 15, No. 2, March 2000, pp. 301-304.	
	33	HADJ TAHAR A et al., entitled "Antidyskinetic effect of JL-18, a clozapine analog, in parkinsonian monkeys," European Journal of Pharmacology, Vol. 399, No. 2-3, July 7, 2000, pp. 183-186.	
	34	ZESIEWICZ TA et al., entitled "Clozapine withdrawal symptoms in a Parkinson's disease patient," Movement Disorders: Vol. 17, No. 6, November 2002, pp. 1365-1367.	
	↓	35	FALTRACO F et al., Aktuelle Therapiemöglichkeiten der Alzheimer Demenz (Current Therapeutical Strategies in Dementia), Neurol Rehabil 2003; 9 (1), pp.15-22.

Examiner Signature	/Umamaheswari Ramachandran/	Date Considered	01/15/2008
--------------------	-----------------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37-CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/725,965
				Filing Date	December 2, 2003
				First Named Inventor	Erik Buntinx
				Art Unit	1617
				Examiner Name	Jennifer M. Kim
Sheet	6	of	6	Attorney Docket Number	29248/18

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/U.R./	36	ETCHEPAREBORDA M C, entitled "Neurocognitive and pharmacological approach to specific learning disorders," Database Medline "Online!, US National Library of Medicine, February 1999, and Revista De Neurologia, Vol. 28, Suppl. 2, February 1999, pp. S81-S93, Abstract.	
	37	STAHL S M et al., entitled "Examination of nighttime sleep-related problems during double-blind, placebo-controlled trials of galantamine in patients with Alzheimer's disease," Current Medical Research and Opinion 2004, Vol. 20, No. 4, 2004, pp. 517-524.	
	38	MENESES A et al., entitled "Are 5-HT (1B/1D) and 5-HT (2A/2B/2C) receptors involved in learning and memory processes?" IDrugs 1999, Vol. 2, No. 8, 1999, pp. 796-801.	
	39	WIRZ-JUSTICE A et al., entitled "Haloperidol disrupts, clozapine reinstates the circadian rest-activity cycle in a patient with early-onset Alzheimer disease," Alzheimer Disease and Associated Disorders, Vol. 14, No. 4, 2000, pp. 212-215.	
	40	FAHS H et al., entitled "Thymoregulateurs Dans L'Agitation et les Troubles Du Comportement Chez le Sujet Dement a Propos de Huit Cas, Anticonvulsivants and Aggressive Behaviors in Alzheimer's Disease. Eight Cases Reports," L'Encephale	
		Vol. 25, No. 2, 1999, pp. 169-174.	
	41	WERTH E et al., entitled "Decline in long-term circadian rest-activity cycle organization in a patient with dementia," Journal of Geriatric Psychiatry and Neurology, Vol. 15, No. 1, April 2002, pp. 55-59.	
	42	MELTZER HY et al., entitled "Plasma clozapine levels and the treatment of L-Dopa-induced psychosis in Parkinson's disease. A high potency effect of clozapine," Neuropsychopharmacology, Vol. 12, No. 1, 1995, pp. 39-45.	
	43	MUNCHAU A et al., entitled "Pharmacological Treatment of Parkinson's Disease," Postgraduate Medical Journal, Vol. 76, October 2000, pp. 602-610.	

Examiner Signature	/Umamaheswari Ramachandran/	Date Considered	01/15/2008
--------------------	-----------------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.